Skip to main content Accessibility help
Hostname: page-component-99c86f546-md8df Total loading time: 0.567 Render date: 2021-12-06T22:14:03.501Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Appendix B - Exploring alternative, collaborative models of innovation for medicines and vaccines1

Published online by Cambridge University Press:  05 June 2012

Tzen Wong
Public Interest Intellectual Property Advisors
Graham Dutfield
University of Leeds
Get access


There has been increasing debate over the appropriateness of the intellectual property (IP) system for the promotion of pharmaceutical innovation and access to medicines. Some have argued that the reason poor countries have difficulty accessing medicines is not related to the IP system, but due to deficient health infrastructures and precarious local sanitation systems in the developing world (International Federation of Pharmaceuticals Manufacturers & Associations [IFPMA] 2004, p. 49). Others have qualified that a differentiation in local infrastructures does not detract from the fact that global structures, including the international IP system, actively shape those local variants and inequities. Among those who think that the IP system is flawed, whether in its design or implementation, there are increasing discussions about finding new and better models of innovation and medical progress. In a recent report by the International Expert Group on Biotechnology, Innovation and Intellectual Property entitled Toward a New Era of Intellectual Property: From Confrontation to Negotiation (‘IEGBIIP Report 2008’), a distinction is made between so-called ‘Old IP’ and an evolving ‘New IP’ era. The former refers to the way the IP system has been interpreted traditionally, mainly using principles of competition and profit-making as the basis for innovation. The core finding of the report is:

[P]olicy-makers and business leaders must give shape to a new era of intellectual property (IP) to stimulate innovation and broaden access to discoveries. The current system, ‘Old IP’, rests on the belief that if some IP is good, more must be better. But such thinking has proved counterproductive to industry, which in health fields has seen declining levels of innovation despite increasing stakes in IP. The era of Old IP has also proved counterproductive to the world's poor who await advances in health and agriculture long available to the global elite.

According to the IEGBIIP Report, the actors involved in research and development (R&D) need a shift in paradigm towards a ‘New IP’ model based on the concept of sharing knowledge rather than hoarding knowledge – a model where IP is viewed as a ‘servant to … values such as equity and fairness’ (ibid., p. 14). This emphasis that IP should be evaluated as a means towards attaining social justice and improving human well-being, rather than simply as an end in itself, echoes the human development paradigm discussed in Chapter 1 of this book. The ‘New IP’ model also reflects cultural factors in the innovation process, along with collective processes as a route towards equitable reforms. Innovation is seen as a social and communal phenomenon, a product of actors collaborating rather than working in isolation. The IEGBIIP Report offers numerous examples of this collaborative approach, including many public-private partnerships (PPPs). From the Public Interest Intellectual Property Advisors (PIIPA) literature review for this book, other examples of alternative, collaborative models for pharmaceutical innovation have been identified. Some models are briefly described here along with challenges or obstacles. Most of the models seek to direct funding to treatments for diseases where traditional market incentives have been insufficient, or explore different means of financing and rewarding research efforts.

Intellectual Property and Human Development
Current Trends and Future Scenarios
, pp. 369 - 375
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Send book to Kindle

To send this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats